Introduction
============

The World Health Organization (WHO) estimates that, every year, more than 20 million people worldwide become infected with the hepatitis E virus (HEV) ([@B82]). Furthermore, it is estimated that 3.3 million of these cases are symptomatic and produce 44,000 deaths ([@B82]). Considering these statistics, the WHO ranks HEV as the leading cause of global acute hepatitis of viral origin. The majority of cases are reported in low-income countries, mainly Asia and Africa, where HEV causes large outbreaks associated with the consumption of contaminated water and is producing by HEV genotypes 1 and 2 ([@B80]). In contrast, in high-income countries, the majority of cases are produced by HEV genotype 3 and are linked to the consumption of contaminated food, including mainly pork-derived products and game meat ([@B23]). Because of the efficient transmission of the infection by this route, the European Food Safety Authority (EFSA) has indicated that HEV infection is a major public health problem in Europe ([@B21]). Although a high proportion of these infections cause self-limiting asymptomatic or subclinical hepatitis ([@B38]), there are clinical situations that can produce a worsened prognosis of the infection ([@B38]; [@B49]), and can even present with acute extrahepatic manifestations ([@B55]); overall alterations in the central and peripheral nervous systems ([@B16]).

HIV-infected patients encompass immunological, epidemiological, and clinical characteristics that can modify the pathogenesis of HEV. In this sense, after an acute HEV infection, the virus can persist and can develop into a chronic infection ([@B40]). Furthermore, the immunosuppression derived from HIV infection can modify the immune response to HEV infection, causing a serological and virological pattern that implies a modification in the diagnosis algorithm ([@B54]; [@B42]). Additionally, in these patients, HEV reinfection has been suggested ([@B65]); thus, extra preventive measures should be recommended in these subjects, even in those with evidence of past HEV infection. Furthermore, in patients with underlying chronic liver diseases (mainly by coinfection with other hepatotropic viruses such as hepatitis C or B), acute HEV infection has a worsened prognosis that is associated with a high mortality rate ([@B53]; [@B18]). Thus, due to the high prevalence of hepatitis C and B coinfection among HIV infected patient, the risk of liver decompensation could be high in this population. Finally, HIV-infected subjects may be at higher risk for HEV acquisition due to HIV infection *per se* or to associated risk practices ([@B52]; [@B61]). Thus, HIV-infected patients represent a population that is highly sensitive to HEV infection. For this reason, in this review, we describe the current knowledge about the epidemiology, diagnosis, clinical manifestations, management and prevention of HEV infection in HIV-infected populations.

Results and Discussion
======================

Search Strategy and Selection Criteria
--------------------------------------

The references used in this review were identified through searches of the PubMed database with the search terms "Hepatitis E," "chronic Hepatitis E," "HIV," and "viral hepatitis" from 1990 until September 2018. Articles were also identified through searches of the authors' own files. Only papers published in English were reviewed. The final reference list was generated on the basis of originality and relevance to the broad scope of this review.

Epidemiology of HEV in HIV-Infected Patients
--------------------------------------------

### Prevalence and Incidence

Studies evaluating the seroprevalence of IgG anti-HEV in HIV-infected subjects were conducted on all continents ([Figure 1](#F1){ref-type="fig"}). Higher seroprevalence was reported in Africa and Asia (exceeding 40% in the majority of countries), followed by continental European Union countries (20--10%) and, finally, the Americas and Oceania (\<10%). Full details of the studies evaluating HEV seroprevalence in HIV-infected individuals are presented in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}. Several studies evaluated HEV seroprevalence in HIV-specific populations. In this sense, three studies evaluated the HEV IgG prevalence in pregnant women with HIV in Africa, reporting a seroprevalence of 7.1% in Gabon ([@B12]), 7.4% in Malawi ([@B47]), and 33.3% in Ethiopia ([@B1]). Finally, the prevalence of HIV-infected patients who are candidates for liver and kidney transplants in the United States was 19.2% ([@B73]). Nevertheless, when interpreting and comparing HEV seroprevalence data, it should be considered that the immune assays used for HEV antibody identification demonstrate different sensitivities ([@B5]). These differences were noted in a recent meta-analysis that included studies conducted in Europe, with the main aim to evaluate the seroprevalence in different subsets of patients according to the serological assays employed ([@B29]). In this study, the seroprevalence rates found in HIV-infected patients were 1.8, 3.75, 5.9, 9.26, 11.55, and 15.69%, depending on the assay used. Similarly, a study conducted in Germany that included 246 HIV-infected individuals reported that the seroprevalence strongly varied from 1.6 to 25.6%, depending on the anti-HEV assays used ([@B57]).
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Few studies have reported HEV seroincidence in HIV-infected patients. Two studies conducted in Spain showed HEV seroincidence rates of 2.4 and 6.5% in 1 year, respectively ([@B54]; [@B64]). In a study that enrolled HIV-infected patients from China, the annual HEV seroincidence was 15.4% ([@B84]). Finally, another study that included HIV-infected pregnant women from Tanzania reported an annual seroincidence of 1% ([@B28]).

### Transmission and Risk Groups

The HEV transmission route varies depending on the viral genotype. HEV genotypes 1 and 2, which exclusively affect humans, are mainly transmitted by the consumption of fecal-contaminated water during the rainy season and are associated with flooding, as noted by the WHO ([@B80]). Similarly, a lack of hygienic measures, such as a lack of hand washing or the absence of proper sanitation, is an important risk factor for the acquisition of HEV in the general population ([@B80]). In a study conducted in Nigeria that enrolled HIV-infected patients, an inadequate toilet system (pit and bush) and water supply source (well and stream) were identified as major risk factors for HEV infection ([@B36]). In contrast, HEV genotypes 3 and 4 as well as the less-common genotype 7 can infect both humans and a wide range of animals; thus, they constitute a zoonotic infectious disease ([@B21]). In the general population, the main routes of transmission of these genotypes are the consumption of raw or undercooked meat (overall pork) and contact with infected animals ([@B21]). In this sense, the HEV seroprevalence in HIV-infected individuals who eat raw/undercooked pork was 33% compared with 9% in those who not reported consumption in a study conducted in southwest England ([@B39]). In addition, one outbreak, which was linked to the consumption of wild boar meat in Spain, that involved HIV-infected patients has been recently reported ([@B66]). Other factors associated with HEV seroprevalence in the general population, such as older age ([@B25]; [@B59]; [@B54]; [@B68]; [@B74]; [@B84]; [@B87]), geographical location or habitat ([@B60]; [@B25]; [@B59]; [@B36]; [@B71]; [@B83]; [@B64]; [@B74]; [@B84]), and male sex ([@B54]; [@B84]; [@B7]), have also been associated with HIV-infected patients. Consequently, the main route of HEV, including all viral genotypes, does not differ between the general and HIV populations.

###### 

Studies evaluating HIV infection as a risk factor for hepatitis E virus infection, including comparator groups.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study references   HIV population (n)   Comparator group (n)                  HEV seroprevalence (%) HIV group   HEV seroprevalence (%) Comparator group   HIV infection identified as risk factor
  ------------------ -------------------- ------------------------------------- ---------------------------------- ----------------------------------------- -----------------------------------------
  [@B52]             146 MSM              135 MSM\                              7.5%                               10.4% MSM\                                No
                                          141 Htx                                                                  3.5% Htx                                  

  [@B39]             138                  464 patients without history of CLD   9.4%                               13.8%                                     No

  [@B59]             72                   896 HD                                19.4%                              11.1%                                     Yes

  [@B71]                                                                                                                                                     

  [@B1]              18 pregnant women    368 pregnant women                    33.3%                              31.5%                                     No

  [@B11]             244                  246 HD                                50.8%                              49.6%                                     No

  [@B45]             60                   896 HD                                23.3%                              29.1%                                     No

  [@B24]             484                  1500 HD                               6.6%                               1.8%                                      Yes

  [@B48]             261                  46 kidney Tx                          1.5%                               6.5%                                      No

  [@B10]             105                  105 HD                                0.95%                              3.8%                                      No

  [@B3]              300                  600 HD                                IgG: 38.7%\                        IgG: 47.3%\                               No
                                                                                IgM: 3.6%                          IgM: 3.8%                                 

  [@B7]              494                  491 HD                                46.4%                              47.7%                                     No

  [@B74]             459                  581 HD                                IgG: 39.4%\                        IgG: 9.5%\                                Yes
                                                                                IgM: 15.3%                         IgM: 4.4%                                 

  [@B36]             80                   190 HD\                               30%                                44.7% healthy donors\                     No
                                          108 pregnant women\                                                      41.6% pregnant women\                     
                                          48 animal handlers                                                       58.3% animal handler                      

  [@B76]             403                  397 HD                                12.9%                              20.2%                                     No

  [@B61]             238                  301 CLD patients\                     9.2%                               4.9% CLD patients\                        Yes
                                          338 Liver Tx\                                                            9.4% Liver Tx\                            
                                          296 Kidney Tx\                                                           3.7% Kidney Tx\                           
                                          200 HD                                                                   3.5% HD                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HIV, human immunodeficiency virus; n, number of subjects; HEV, hepatitis E virus; MSM, men who have sex with men; Htx, heterosexual; HD, healthy donors; HCV, hepatitis C virus; CLD, chronic liver disease; Liver Tx, liver transplant; Kidney Tx, kidney transplant.

Several studies have evaluated whether HIV infection constitutes a risk factor for HEV infection ([Table 1](#T1){ref-type="table"}) ([@B24]; [@B39]; [@B48]; [@B59]; [@B52]; [@B36]; [@B61]; [@B71]; [@B76]; [@B45]; [@B1]; [@B3]; [@B10],[@B11]; [@B74]; [@B7]). Of these studies, only three matched the controls by age, sex and geographical area ([@B3]; [@B10]; [@B7]). Consequently, HIV *per se* seems not to be a risk factor for HEV infection. Other not matched studies found differences in favor to healthy donors or HIV infected patients. A study conducted in Uganda that included 491 healthy blood donors and 494 HIV-infected patients showed no differences in terms of HEV IgG seroprevalence between both groups (47.7 and 46.4%) ([@B7]). Another study performed in Poland showed a relatively higher HEV seroprevalence in healthy donors (3.8%) than that in subjects infected with HIV (0.95%) ([@B10]). Similarly, in a French study, the HEV IgG seroprevalence in healthy donors was higher than that in HIV-infected patients (47.3 and 38.7%) ([@B3]).

Specific conditions related to HIV infection have been evaluated as potential factors associated with HEV infection. First, HIV viremia seems to have no association with a higher risk for HEV infection ([@B34]; [@B39]; [@B54]; [@B68]; [@B3]; [@B26]). Therefore, the rate of IgG HEV antibodies is similar among patients with detectable and undetectable HIV viral loads ([@B34]; [@B39]; [@B54]; [@B68]; [@B3]; [@B26]). In the same way, the use and duration of antiretroviral therapy has not been associated with a higher HEV seroprevalence in different studies that have reported a comparable percentage between patients on antiretroviral therapy and those not using this type of therapy ([@B34]; [@B39]; [@B25]; [@B54]; [@B68]; [@B3]; [@B26]). Furthermore, one study did not find differences in HEV seroprevalence between HIV-1- and HIV-2-infected patients ([@B37]). Finally, studies evaluating the association between CD4+ cell count and HEV seroprevalence present controversial results. The majority of these studies found a similar HEV seroprevalence between patients with a CD4+ cell count that was either higher or lower than 200 cells/mL ([@B37]; [@B40]; [@B34]; [@B54]; [@B11]; [@B26]), or when a cut-off of 250 cells/mm^3^ was applied ([@B84]). Nevertheless, there are studies that found a higher HEV seroprevalence in patients with a total CD4+ cell count higher than 200 cells/mL ([@B40]), while other studies found the opposite effect, in that patients with a CD4+ count below 200 cells/mL showed a higher seroprevalence of IgG antibodies ([@B60]; [@B20]; [@B87]).

Several observations have suggested that men who have sex with men (MSM) may be exposed to an increased risk for HEV transmission. In a study conducted in the United Kingdom (UK), the seroprevalence of HEV was compared among 146 HIV-infected MSM, 135 HIV-non-infected MSM, and 141 HIV-non-infected heterosexual men. The seroprevalence was similar between both MSM groups (7.5% vs. 10.4%; *p* = 0.4) but was higher than that found in heterosexual men (3.5%; *p* = 0.025) ([@B52]). Similarly, in an Italian study in which the HEV seroprevalence was evaluated in a large cohort of individuals that included HIV-infected patients, the seroprevalence found in MSM was higher than the seroprevalence reported in non-MSM (7.5% vs. 4.7%; *p* = 0.04) ([@B43]). Finally, another Italian study analyzed the seroprevalence of HEV and hepatitis A virus (HAV) in a cohort of 636 MSM and compared the seroprevalence with that of a control group of 288 non-MSM ([@B27]). This study reported a higher seroprevalence for both HAV and HEV (42.8 and 10.2%) in the MSM group than that in the non-MSM group (29.2 and 5.2%). In contrast, a recent study conducted in Taiwan during an HAV outbreak including 3,293 HIV-infected patients, majoritarian MSM, the seroprevalence and seroincidence of HEV infection did not differ between sexual risk practice or underlying infection (HAV, HCV, or Syphilis) ([@B44]). Interestingly, in only 1 of the 23 HEV seroconversion documented in the study also showed seroconversion for HAV. For this reason, the fact that HIV-infected MSM might be a population that is at higher risk for HEV acquisition need to be clarify.

Diagnosis of HEV Infection in HIV-Infected Patients
---------------------------------------------------

The virological markers for the diagnosis of HEV infection comprise viral components (HEV RNA and HEV Antigen \[HEV Ag\]) and products related to the host immune response (anti-HEV specific antibodies of IgA, IgG, and IgM classes) ([@B5]). Typically, in the general population, after an incubation period between 2 and 6 weeks, viral RNA and HEV Ag are detectable in the blood, urine, and feces ([@B86]). After 4--6 weeks of infection, HEV-RNA is usually undetectable in the blood but can remain detectable in the feces for several weeks ([@B5]). The immune response follows a typical pattern of seroconversion with an initial and transient increase in IgM that leads to a sustained IgG response. Anti-HEV IgM antibodies are detected only during the acute phase and remain detectable up to the 5th month after infection, making these antibodies the best serological markers for the diagnosis of acute HEV infection. Furthermore, IgG antibodies can be detected very close in time to the detection of IgM antibodies, and they remain detectable for more than 10 years; thus, they may be used to establish past exposure to HEV ([@B5]). Finally, IgA antibodies can also be detected during the acute phase of HEV infection, but their use in the diagnosis of HEV infection is controversial ([@B5]).

Studies have evaluated the prevalence of HEV IgM antibodies in HIV-infected patients, and they have found a good value for the diagnosis of acute/recent HEV infection in this population ([@B3]; [@B74]). Furthermore, several studies have shown that the absence of HEV-IgM antibodies is correlated with the absence of HEV RNA in HIV-infected patients ([@B58]; [@B28]), even in patients with severe immunosuppression ([@B51]; [@B67]). In addition, several studies of HEV infection show that HEV-IgM positivity coincides with the first detectable HEV viral load ([@B60]; [@B72]; [@B8]; [@B69]; [@B3]). In contrast, there is evidence that the use of HEV IgM to diagnose acute HEV infection in this population has limited value because studies have shown that HIV-infected patients may have a delayed immune response or may lack an immune response against acute HEV infection. One of these studies, in which three cases of acute HEV infection were described, showed that all cases lacked HEV IgM positivity and seroconversion over time; additionally, they all showed a CD4+ count higher than 200 cells/mm^3^ ([@B42]). Similarly, another study that included 5 cases of acute HEV infection diagnosed by HEV RNA found that HEV IgM could only be detected at diagnosis in two subjects ([@B68]), and three of these patients lacked HEV IgM positivity, with a CD4+ cell count higher than 200 cells/mm^3^. Similarly, in a study of 10 cases of acute HEV infection in Brazil, none of the patients presented with HEV HEV IgM, or HEV IgG antibodies ([@B70]). Of the 9 patients with an available CD4+ count, only one showed a CD4+ cell count lower than 200 cells/mL ([@B70]). These data show that the lack of HEV IgM during the acute phase may not be limited to those patients with severe immunosuppression. For these reasons, in HIV-infected patients, the application of HEV IgM alone may not be sufficient to exclude the diagnosis of acute HEV infection, and it is mandatory to include a direct diagnosis procedure such as HEV RNA ([@B22]; [@B62]).

After the occurrence of the acute phase in HIV-infected patients, HEV can persist and may develop into a chronic infection, which is defined as the persistence of HEV RNA for more than 3 months ([@B22]; [@B62]). In these patients, IgM and IgG antibody seroconversion is usually absent or can be detected intermittently ([@B13]; [@B15]; [@B37]; [@B40]; [@B6]; [@B33]; [@B50]; [@B32]; [@B42]; [@B77]). On the other hand, it has been described that in HIV infected patients HEV reinfection may occur ([@B65]). The serological pattern of HEV reinfection is characterized by the presence of HEV RNA with positivity to HEV IgG antibodies and the persistent absence of HEV IgM ([@B22]; [@B62]). Thus, the only marker that is indicative of these two virological situations is the use of methods evaluating HEV RNA.

Clinical Impact of HEV Infection in HIV-Infected Patients
---------------------------------------------------------

Acute HEV infection usually occurs as mild-severity acute hepatitis in both the general and HIV-infected populations. In several patients, hospitalization is necessary ([@B38]), with an associated mortality of up to 8.7%, which varies depending on the comorbidities of the patients affected ([@B53]; [@B18]). In patients with underlying chronic liver disease, acute HEV infection is associated with a high overall mortality rate in patients from low-income countries who are infected with HEV genotypes 1 and 2 ([@B41]). Several studies have evaluated the prevalence of acute HEV infection in HIV-infected patients with acute increases in transaminases. In a study conducted in Scotland of 99 HIV-infected patients, the prevalence of acute HEV was 1.06% ([@B9]). Another study performed in France found that acute HEV infection was a cause of unexplained elevated transaminases in one patient of the 108 HIV-infected subjects evaluated (0.9%) ([@B72]). In the United States, among 458 HIV-infected patients who were United States military beneficiaries, evidence of acute HEV infection was detected in 4% of 194 HIV-infected persons with an episode of increased transaminase levels ([@B14]). In contrast, a study that included 256 HIV-infected patients at follow-up in the Netherlands did not find any cases of acute HEV ([@B30]). For this reason, clinical guidelines recommend excluding HEV in cases of acute hepatitis ([@B22]; [@B62]). Until today, no hepatic decompensation among HIV cirrhotic patients has been reported.

Furthermore, there is increasing knowledge regarding extrahepatic manifestations that are linked to acute HEV infection, highlighting neurological injury, renal injury, cryoglobulinemia, pancreatitis, and hematological disorders ([@B16]; [@B55]). Although there are no specific studies that describe the course of HEV infection with extrahepatic manifestations in HIV-infected patients, the cases reported in this population suggest a similar clinical pattern to that reported in a non-HIV-infected population during the acute phase ([@B8]; [@B69]; [@B42]). Nevertheless, in a series of cases that included both immunocompetent and immunocompromised patients (with only three HIV-infected patients in this group), it was suggested that acute hepatitis-related symptoms and neurological manifestations may occur at lower frequencies in immunocompromised patients ([@B4]).

###### 

Cases of chronic hepatitis E virus infection in HIV-infected patients.

  Case references   Gender   Age   CD4+ cells count   HEV anti IgM/IgG   HEV genotype   Duration of HEV viremia (months)   Outcome                       Comment
  ----------------- -------- ----- ------------------ ------------------ -------------- ---------------------------------- ----------------------------- -------------------------------------------------------------------------------------------------
  [@B15]            Male     48    \<100              Pos/Pos            3a             24                                 Treatment initiation          
  [@B13]            Male     50    \<100              Neg/Neg            3              12                                 Not reported                  
  [@B33]            Male     45    54                 Neg/Neg            3a             132                                Treatment initiation          
  [@B37]            Male     44    40                 Pos/Neg            3f             10                                 Deceased                      Diagnosis of chronic infection coincides with treatment time for non-Hodgkin's lymphoma therapy
  [@B40]            Male     46    34                 NT/Pos             3b             36                                 Spontaneous viral clearance   Viral clearance after CD4+ count increases
  [@B40]            Male     59    50                 NT/Neg             3c             At least 6                         Spontaneous viral clearance   
  [@B6]             Male     42    37                 Neg/Neg            3              36                                 Spontaneous viral clearance   Clearance after HAART initiation and CD4+ count restoration
  [@B50]            Male     47    \<200              Pos/Neg            3              36                                 Treatment initiation          
  [@B50]            Male     53    \<200              Neg/Pos            3              60                                 Treatment initiation          
  [@B42]            Female   --    \<200              Neg/Neg            3a             36                                 Not reported                  
  [@B32]            Male     47    \<200              Pos/Pos            3              48                                 Treatment initiation          
  [@B77]            Male     59    \<100              NT/NT              3i             48                                 Treatment initiation          

CD4+, lymphocytes CD4+; HEV, hepatitis E virus; IgM, immunoglobulin M; IgG, immunoglobulin G; Pos, positive; Neg, negative; NT, non-tested.

###### 

Treatment of acute and chronic HEV in HIV-infected patients.

  -----------------------------------------------------------------------------------------------------------------
  Phase     References   HEV genotype   Regimen                                 Outcome
  --------- ------------ -------------- --------------------------------------- -----------------------------------
  Acute     [@B3]        3f             RBV 24 weeks                            Treatment induced viral clearance

  Acute     [@B69]       3c             RBV 24 weeks 1,200 mg                   Treatment induced viral clearance

  Acute     [@B8]        3c             RBV 24 weeks 1,200 mg                   Treatment induced viral clearance

  Chronic   [@B17]       3a             Peg-IFN 24 and 6 weeks of Peg-IFN/RBV   Treatment induced viral clearance

  Chronic   [@B33]       3a             Peg-IFN 24 weeks                        Treatment induced viral clearance

  Chronic   [@B50]       3              RBV 24 weeks 1,200 mg                   Viral relapse

  Chronic   [@B50]       3              RBV 24 weeks 1,000 mg                   Viral relapse

  Chronic   [@B32]       3              RBV 20 weeks 800 mg                     Treatment induced viral clearance

  Chronic   [@B77]       3i             1° Peg-IFN/RBV 12 weeks\                1° Viral relapse\
                                        2° SOF/RBV 12 weeks                     2° Viral relapse
  -----------------------------------------------------------------------------------------------------------------

HEV, hepatitis E virus; RBV, ribavirin; Peg-IFN, pegylated interferon; SOF, sofosbuvir.

Furthermore, 4--6 weeks after the appearance of clinical symptoms, the infection is usually self-limited and does not need therapy. However, in immunosuppressed patients with various causes, the infection can evolve into a chronic infection ([@B22]; [@B62]). This development usually occurs with HEV genotypes 3 and 4 and is characterized by a rapid progression to liver cirrhosis and the persistence of changes at the transaminase level ([@B50]). The prevalence of chronic HEV infection among HIV-infected patients is rare, with an estimated prevalence between 0 and 0.5% ([@B46]; [@B56]; [@B60]; [@B72]; [@B48]; [@B71]; [@B73]; [@B51]; [@B68]; [@B3]; [@B26]). In a Spanish study, the prevalence of chronic HEV infection among HIV-infected patients with unexplained increases in liver stiffness was 0.5% ([@B63]). In two cohorts of HIV-infected patients from France and the United States, the prevalence of chronic HEV infection was 0.5 and 0.05%, respectively ([@B37]; [@B42]). Finally, in a study conducted in Switzerland that included 735 HIV-infected patients with persistent ALT levels, the prevalence of chronic HEV infection was 0.13% ([@B40]). Currently, 12 cases of chronic HEV infection have been reported in HIV-infected patients ([Table 2](#T2){ref-type="table"}) ([@B13]; [@B15]; [@B37]; [@B40]; [@B6]; [@B33]; [@B50]; [@B32]; [@B42]; [@B77]). All HIV cases have a CD4+ cell count lower than 200 cells/mm^3^, which is the only risk factor associated with the development of chronic HEV infection in this population.

Treatment of Acute and Chronic HEV Infection in HIV-Infected Patients
---------------------------------------------------------------------

Most cases of acute HEV infection are self-limited without the need for the implementation of therapy in both the general and HIV-infected populations. However, in several subsets of patients, such as patients with underlying chronic liver disease or acute liver failure, acute HEV infection is associated with a higher risk of complications and a worse prognosis ([@B41]). Currently, there are no specific therapies available against acute HEV infection ([@B22]; [@B62]). The evidence available regarding the use of ribavirin (RBV) in the HIV-infected population for the treatment of acute HEV infection is limited to three cases of infection with genotype 3 ([Table 3](#T3){ref-type="table"}), all of which were successfully treated with RBV monotherapy for 12 or 24 weeks ([@B8]; [@B69]; [@B3]).

The development of chronic HEV infection is associated with immunosuppression; thus, measures aimed at restoring the immune response may induce the clearance of HEV ([@B22]; [@B62]). In this sense, two cases of chronic HEV infection in HIV-infected patients were self-limiting after the initiation of antiretroviral therapy and the suppression of HIV viral load ([Table 2](#T2){ref-type="table"}) ([@B40]; [@B6]). Relatively large amounts of evidence regarding the therapeutic options for chronic HEV infection are available for liver transplant patients ([@B49]). In contrast, evidence in HIV-infected patients is scarce and limited to the description of 6 cases ([Table 3](#T3){ref-type="table"}). Three cases have reported treatment with RBV monotherapy ([@B50]; [@B32]), and two of these patients experienced viral relapse after the cessation of therapy \[63\]. Another three cases reported the combination of pegylated interferon with RBV for 12 and 24 weeks of treatment ([@B17]; [@B33]; [@B77]), and two of these patients attained sustained viral clearance ([@B17]; [@B33]). Finally, the *in vitro* antiviral activity of sofosbuvir against HEV has been demonstrated ([@B19]). Nevertheless, the use of this drug in the transplant population for the treatment of chronic HEV has not been demonstrated to have efficacy in eliminating the virus ([@B79]; [@B78]). In the HIV-infected population, the use of sofosbuvir in combination with RBV for 12 weeks has been evaluated in only one case ([@B77]). This patient experienced viral relapse after the completion of therapy.

Prevention of HEV in HIV-Infected Patients
------------------------------------------

The most effective preventative measure for HEV infection is to avoid contact with the source of infection, such as avoiding the consumption of raw/undercooked food where HEV has been isolated or the consumption of unchlorinated contaminated water in low-income countries ([@B22]; [@B62]). Treating meat at a temperature of 70°C for 30 min has been shown to strongly inhibit HEV activity ([@B35]). For contaminated milk, thermal treatment at 100°C has shown complete inactivation of the virus ([@B31]). For contaminated water, a chlorine dose of 5 mg/L for 15 min appears to be sufficient to reduce the HEV viral load; nevertheless, it may be necessary to increase the chlorine dose if water contains solid material ([@B80]; [@B21]). Clinical guidelines recommend that immunocompromised patients, such HIV-infected patients with a CD4+ cell count below 200 cells/mm^3^ and those with chronic liver disease including HIV-infected patients with coinfection with HCV or HBV, should avoid the consumption of raw or undercooked meat and shellfish due to the risk of developing a serious or even fatal course of HEV infection ([@B22]; [@B62]).

Currently, there is only one vaccine available for the prevention of HEV infection, which is a recombinant vaccine against genotype 1 that has demonstrated high protection of up to 5 years for people over 16 years of age, with potential protection of up to 30 years ([@B85]; [@B75]). Nevertheless, the application of this vaccine is currently limited to China, following the position of the WHO ([@B81]). This position is supported by the fact that there are no clinical trials evaluating the safety and efficacy of this vaccine in populations susceptible to a worsened prognosis of the disease (HIV-infected patients, transplant recipients, pregnant women, and patients with underlying chronic liver disease) and because of only demonstrated efficacy in preventing HEV genotype 1 infection. For this reason, the WHO recommends that vaccination should be considered individually in people who plan to travel to an area where an epidemic is occurring (e.g., aid workers and health workers).

Finally, in immunosuppressed patients, such as transplant recipients and HIV-infected patients ([@B2]; [@B65]), HEV reinfection has been described. Furthermore, in immunocompetent patients, an IgG antibody concentration of 2.5 WHO units/mL could protect against reinfection ([@B85]); in immunocompromised patients, this titre can be increased up to 7 WHO units/mL ([@B2]). Nevertheless, there are no data regarding the minimum protective titre of IgG antibodies in HIV-infected patients. This fact reinforces the recommendation that preventive measures should be applied in immunosuppressed HIV-infected patients, even in the presence of IgG antibodies. Furthermore, due to the risk of reinfection and the lack of diagnostic value of IgM antibodies at this point, annual testing for HEV-RNA in HIV immunocompromised patients is currently recommended in clinical guidelines ([@B22]; [@B62]).

Conclusion
==========

Despite the increasing knowledge about the pathogenesis, epidemiology and clinical impact of HEV infection, several major factors are faced by HIV-infected patients. First, HIV infection seems not to be a risk factor for HEV acquisition. Nevertheless, the risk population for HIV infection, such as MSM, may also have a higher risk for HEV infection. A better understanding of this risk significantly increases the awareness of prevention in this population. Second, in recent years, HEV-associated extrahepatic manifestations have been described, with special emphasis on acute neurological injury. However, there is a lack of clinical data on these extrahepatic manifestations in HIV-infected patients; thus, there is no evidence on the frequency, clinical course and management that can support any special recommendations. Third, therapy for both acute and chronic HEV infections is suboptimal, with very limited evidence for combination and posology therapies in the HIV-infected population. The use of direct-acting viral drugs, such as sofosbuvir, against other viral infections has shown a lack of efficacy in clinical practice in terms of chronic HEV infection in both the general and HIV populations. Therefore, evaluating alternative therapeutic options is a priority. Finally, the only approved vaccine for preventing HEV infection has a lack of data regarding safety and efficacy in HIV-infected patients. Thus, before vaccination of these patients, there is a need for data as well as the overall evaluation of the persistence of protected antibodies over time in severely immunocompromised HIV patients.
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